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he Relation of Dosing to Clopidogrel Responsiveness
nd the Incidence of High Post-Treatment Platelet
ggregation in Patients Undergoing Coronary Stenting
aul A. Gurbel, MD, FACC, Kevin P. Bliden, BS, Kevin M. Hayes, DO, Jason A. Yoho, MD,
illiam R. Herzog, MD, FACC, Udaya S. Tantry, PHD
altimore, Maryland
OBJECTIVES We determined the effect of clopidogrel dosing on the incidence of nonresponsiveness (NR)
and high post-treatment platelet aggregation (post-PA).
BACKGROUND We have reported NR after a 300-mg loading dose. Limited information is available on the
comparative effect of a 600-mg loading dose on the incidence of NR and high post-PA.
METHODS Clopidogrel responsiveness and post-PA were measured in patients undergoing stenting
(n  190) randomly treated with either a 300-mg or a 600-mg clopidogrel load. Nonre-
sponsiveness was defined as10% absolute change in platelet aggregation, and high post-PA
was defined as 75th percentile aggregation after 300 mg clopidogrel.
RESULTS Nonresponsiveness was lower after 600 mg compared to the 300-mg dose (8% vs. 28% and
8% vs. 32% with 5 and 20 M ADP, respectively, p 0.001). Among the patients with high
post-PA after 300 mg clopidogrel, 62% to 65% had NR, whereas after the 600-mg dose, all
of the patients with high post-PA had NR.
CONCLUSIONS A 600-mg clopidogrel loading dose reduces the incidence of NR and high post-PA as
compared to a 300-mg dose. Higher dosing strategies and methods to confirm platelet
inhibition should be further investigated in order to optimally use clopidogrel in patients
undergoing stenting. (J Am Coll Cardiol 2005;45:1392–6) © 2005 by the American
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.01.030College of Cardiology Foundation
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te have reported response variability and nonresponsive-
ess (NR) after a 300-mg clopidogrel loading dose for
oronary artery stenting (1). Since then other studies have
onfirmed that some patients do not achieve optimal plate-
et inhibition and exhibit NR after standard clopidogrel
herapy (2–4). The mechanisms responsible for NR are
ncompletely defined; variability in intestinal absorption and
he hepatic cytochrome P450 3A4 activity were reported as
mportant factors (5–7).
Muller et al. (3) reported an 11% incidence of NR after a
00-mg loading dose versus the 31% incidence after a
00-mg loading dose reported in our previous study (1). In
small study (n 10 per group), the same investigators also
eported that a 600-mg clopidogrel loading dose provides
uperior early inhibition (8). Recently, a study of 50 patients
lso suggested that 600 mg clopidogrel was associated with
lower incidence of NR (9). Moreover, Kastrati et al. (10)
ound that patients on a 75-mg maintenance dose achieved
dditional platelet inhibition after treatment with a 600-mg
oad. These findings may be relevant to the occurrence of
tent thrombosis in selected patients (11,12). We have
ecently observed higher post-treatment platelet aggregation
post-PA) in patients who developed stent thrombosis and
From the Sinai Center for Thrombosis Research, Baltimore, Maryland. This study
as supported by the Sinai Center for Thrombosis Research, Baltimore, Maryland.m
Manuscript received November 12, 2004; revised manuscript received December
0, 2004, accepted January 11, 2005.ix-month postprocedure ischemic complications as com-
ared to patients without these events (13,14).
Based on the limited available data, we hypothesized that
R is directly related to the loading dose. We, therefore,
onducted a prospective investigation of platelet aggregation
nd clopidogrel responsiveness after 300-mg and 600-mg
oading doses in patients undergoing elective coronary
tenting.
ETHODS
atients. The Investigational Review Board of the Sinai
ospital of Baltimore approved the study. Patients under-
oing elective coronary stenting (n  190) were studied.
he exclusion criteria included history of bleeding diathesis,
cute myocardial infarction within 48 h, cerebrovascular
vent within 3 months, illicit drug or alcohol abuse, pro-
hrombin time 1.5 times control, platelet count
100,000/mm3, hematocrit 30%, creatinine 4.0 mg/dl,
nd thienopyridine or glycoprotein (GP) IIb/IIIa inhibitor
se before the procedure.
All patients received aspirin (81 to 325 mg) for at least
even days before the procedure and were given 325 mg of
spirin on the day of the procedure and daily thereafter.
atients were randomly administered a loading dose of 300
g or 600 mg clopidogrel in the catheterization laboratory
mmediately after successful coronary stenting in a three-
o-one distribution, followed by a maintenance dose of 75
g daily. Heparin was administered to all patients (acti-
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May 3, 2005:1392–6 Clopidogrel Nonresponsiveness and Dosingated clotting time 300 s in patients treated without GP
Ib/IIIa inhibitors and 200 to 250 s in patients treated with
P IIb/IIIa inhibitors).
lood samples. Blood was collected as previously de-
cribed in 3.8% trisodium citrate at baseline immediately
efore the procedure and before heparin and GP IIb/IIIa
dministration, and at 24 h after the procedure in those
atients not receiving GP IIb/IIIa inhibitors, and at five
ays after the procedure in those treated with GP IIb/IIIa
nhibitors (1). The rationale for the time of blood sampling
as to avoid an antiplatelet effect from the GP IIb/IIIa
nhibitor. Previous investigations have demonstrated a max-
mum antiplatelet effect after 300-mg and 600-mg clopi-
ogrel loading doses at 24 h after the procedure and no
ffect on the level of inhibition at five days after the pro-
edure (1,15).
latelet aggregation. The blood-citrate mixture was cen-
rifuged at 120 g for 5 min to recover platelet-rich plasma
nd at 850 g for 5 min to recover platelet poor plasma
PPP). Platelets were stimulated with 5 and 20 M aden-
able 1. Patient Demographics
300 mg
Clopidogrel
(n  138)
600 mg
Clopidogrel
(n  52)
p
Value
ge (yrs) 65  13 60  20 NS
ace (Caucasian) (%) 75 75 NS
ender (male) (%) 58 61 NS
isk factors (%)
Smoking 55 66 0.09
Family history of CAD 51 65 0.04
Hypertension 68 78 NS
Hyperlipidemia 67 83 0.01
Diabetes 43 33 NS
Prior myocardial infarction 29 30 NS
Prior CABG 18 13 NS
Prior PTCA 30 28 NS
retreatment medications (%)
Beta-blockers 72 90 0.004
ACE inhibitors 67 72 NS
Calcium blockers 17 20 NS
Lipid-lowering agents 69 72 NS
rocedural variables
Total lesion length (mm) 19  11 21  14 NS
Reference vessel diameter (mm) 3.0  0.4 3.1  0.5 NS
Number of vessels per patient 1.4  0.4 1.4  0.7 NS
CE  angiotensin-converting enzyme; CABG  coronary artery bypass graft
Abbreviations and Acronyms
ADP  adenosine diphosphate
GP  glycoprotein
IR  intermediate responsiveness
NR  nonresponsiveness
post-PA  post-treatment platelet aggregation
PPP  platelet poor plasma
A  absolute change in platelet aggregationurgery; CAD  coronary artery disease; PTCA  percutaneous coronary angio-
lasty. Asine diphosphate (ADP) (Chronolog, Haverton, Pennsyl-
ania), and aggregation was assessed using a Chronolog
umi-aggregometer (Model 490) as previously described
1). Platelet aggregation was expressed as the maximal
ercent change in light transmittance from baseline, using
PP as a reference.
efinitions. High post-PA was defined as 75th percen-
ile aggregation in response to 5 and 20 M ADP in
atients treated with a 300-mg loading dose, intermediate
ost-PA was defined as 50th to 75th percentile aggregation,
nd low post-PA was defined as 50th percentile aggrega-
ion. Clopidogrel responsiveness was determined by the
bsolute change in aggregation (A), where A is the base-
ine aggregation minus the post-treatment aggregation; NR
as defined as a A 10%, intermediate responsiveness as
A  10% to 30%, and responsiveness as a A 30%
1,3). The distribution of responsiveness to clopidogrel in
ach group is represented by histograms as previously
eported (1,16).
tatistical analysis. Comparisons were made between
roups by using t tests, and p  0.05 was considered
ignificant. Curves were plotted of the best fit to a normal
istribution by Statistica software (Tulsa, Oklahoma).
ased on the normal distribution of data, the mean  SD
as used. Categorical variables are expressed as percentages.
ESULTS
emographics. Overall, the groups were well-matched
xcept that hyperlipidemia, family history of coronary artery
isease, and beta-blocker use were higher in the group
reated with 600 mg clopidogrel (Table 1). The percentage
able 2. 5 M ADP-Induced Aggregation and Clopidogrel
esponsiveness
300 mg
Clopidogrel
600 mg
Clopidogrel p Value
re-PA (%) 59  14 63  7 NS
ost-PA (%) 40  16 34  15 0.02
A (%) 20  18 30  13 0.001
R 28% 8% 0.003
R 52% 57% NS
20% 35% 0.03
DP  adenosine diphosphate; IR  intermediate responders; NR  nonre-
ponders; Post-PA  post-treatment platelet aggregation; Pre-PA  pretreatment
latelet aggregation; R  responders; A  change in aggregation.
able 3. 20 M ADP-Induced Aggregation and Clopidogrel
esponsiveness
300 mg
Clopidogrel
600 mg
Clopidogrel p Value
re-PA (%) 76  17 76  8 NS
ost-PA (%) 60  12 49  13 0.001
A (%) 16  6 29  18 0.001
R 32% 8% 0.001
R 47% 55% NS
21% 37% 0.02bbreviations as in Table 2.
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Clopidogrel Nonresponsiveness and Dosing May 3, 2005:1392–6f patients treated with GP IIb/IIIa inhibitors was 28% in
he 300-mg group and 50% in the 600-mg group (p 
.05).
retreatment platelet aggregation and post-PA. Pre-
reatment 5 M and 20 M ADP-induced aggregation in
he 300-mg clopidogrel group did not differ from the
00-mg group (Tables 2 and 3). A 600-mg loading dose
roduced lower 5 and 20 M ADP-induced platelet aggre-
ation (Tables 2 and 3).
igure 1. (A) Distribution of post-treatment platelet aggregation as
easured by 5 M adenosine diphosphate (ADP)-induced aggregation.
istribution is shifted leftward for the 600-mg group, indicating lower
eactivity to ADP. (B) Distribution of post-treatment platelet aggregation
s measured by 20 M ADP-induced aggregation. Distribution is shifted
eftward for the 600-mg group, indicating lower reactivity to ADP.igure 3. Relation of post-treatment platelet aggregation (Post-PA) to nonrespo
iphosphate-induced aggregation.The 75th percentile post-PA cutpoint in the 300-mg
lopidogrel group was 52% as induced by 5 M ADP and
0% as induced by 20 M ADP; post-PA followed a
ormal distribution that was narrower in the patients treated
ith 600 mg clopidogrel (Figs. 1A and 1B). The distribu-
igure 2. (A) Distribution of the absolute change in 5 M adenosine
iphosphate (ADP)-induced aggregation (A). All of the patients under
he double-headed arrow meet the definition for nonresponsiveness (NR).
he distribution is shifted rightward in the 600-mg group, indicating
reater inhibition (responsiveness to clopidogrel). (B) Distribution of the
bsolute change in 20 M ADP-induced aggregation (A). All of the
atients under the double-headed arrow meet the definition for NR. The
istribution is shifted rightward in the 600-mg group, indicating greater
nhibition (responsiveness to clopidogrel).nsiveness in 300- and 600-mg groups as measured by 5 M adenosine-
t
6
p
C
i
n
d
i
d
c
A
6
[
t
h
R
a
h
c
a
w
m
r
r
D
T
l
p
w
b
3
p
d

i
c
m
C
l
t
P
t
i
w
r
U
t
c
p
i
r
e
b
1
a
o
i
s
a
g
p
s
g
e
s
t
(
C
d
l
i
s
F
a
1395JACC Vol. 45, No. 9, 2005 Gurbel et al.
May 3, 2005:1392–6 Clopidogrel Nonresponsiveness and Dosingion of post-PA shifted leftward for the group treated with
00 mg clopidogrel, indicative of a superior overall anti-
latelet effect.
lopidogrel responsiveness. There were more responders
n the 600 mg group (Tables 2 and 3). There was also a
ormal distribution of clopidogrel responsiveness after both
oses of clopidogrel (Figs. 2A and 2B). The response curve
s narrower and is shifted rightward for the 600-mg clopi-
ogrel group, indicating its greater antiplatelet effect as
ompared to the 300-mg group; A after 5 M and 20 M
DP was lower in the 300-mg group as compared to the
00-mg group (p  0.001 for both agonist concentrations
Tables 2 and 3]). Figures 2A and 2B clearly demonstrate
hat the incidence of NR was significantly reduced by the
igher loading dose.
elation of high post-PA to clopidogrel NR. Figures 3
nd 4 demonstrate that most patients with high post-PA
ad NR irrespective of the loading dose or the agonist
oncentration and that35% of patients with high post-PA
fter a 300-mg loading dose of clopidogrel were responsive,
hereas none of the patients with high post-PA after 600
g were responsive. These data suggest that most patients
esponsive to clopidogrel can achieve low post-treatment
eactivity by a high loading dose.
ISCUSSION
he present study demonstrated that a 600-mg clopidogrel
oading strategy produces a superior antiplatelet effect in
atients undergoing elective coronary stenting as compared
ith the standard 300-mg loading dose. This statement is
ased on findings of: 1) lower post-PA; 2) greater A; and
) a lower NR after 600 mg clopidogrel. The degree of
ost-PA is concordant with our earlier investigations that
emonstrated 32% aggregation induced by 5 M ADP,
57% aggregation induced by 20 M ADP, and 31%
ncidence of NR at 24 h after loading with 300 mg
lopidogrel (1,15).
igure 4. Relation of post-treatment platelet aggregation (Post-PA) t
denosine-diphosphate-induced aggregation.Controversy exists in the interventional cardiology com- aunity regarding the optimal loading dose of clopidogrel.
urrently, 300 mg is the most widely prescribed clopidogrel
oading dose in the U.S. Based on information derived from
he Can Rapid Risk Stratification of Unstable Angina
atients Suppress Adverse Outcomes with Early Implimen-
ation of the ACC/AHAGuidelines (CRUSADE) registry,
n the first six months of 2004, 90% of patients presenting
ith a non–ST-segment elevation acute coronary syndrome
eceived 300 mg clopidogrel (Dr. Eric Peterson, Duke
niversity, Durham, North Carolina, personal communica-
ion, November 2004). Stent thrombosis remains a signifi-
ant clinical problem (17). High post-PA and NR are
ossible risk factors for stent thrombosis and the late
schemic events. Recent studies have strongly supported this
elation and suggest that a 300-mg load is not potent
nough in some patients to overcome the thrombotic
urden during and after percutaneous interventions (4,11–
4). Low adverse event rates observed by Kastrati et al. (10)
fter pretreatment with 600 mg clopidogrel strongly support
ur findings of superior platelet inhibition with this dose.
Although clopidogrel responsiveness directly affects the
ncidence of high post-PA, it may overestimate the risk of
tent thrombosis in nonresponders with low pretreatment
ggregation. In the present study and in a previous investi-
ation, we have demonstrated that some patients with low
ost-PA are clopidogrel nonresponsive, whereas some re-
ponders will continue to have high post-treatment aggre-
ation (18). Therefore, we believe that post-PA is a better
stimate of thrombotic risk rather than clopidogrel respon-
iveness. Recent studies from our center and others support
he importance of high post-PA as an important risk factor
3,12–14).
onclusions. Estimates of clopidogrel NR are clearly
ose-dependent. A 600-mg loading dose is associated with
ower post-PA, and, thus, 600 mg should be further
nvestigated as the new standard therapy. Our data strongly
upport the importance of insufficient metabolite generation
responsiveness in 300- and 600-mg groups as measured by 20 Mo nons the primary explanation for NR. In addition to higher
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latelet reactivity after treatment should be further studied
n order to optimally use this drug.
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